Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (511-520 of 993) with videos related to

Pageof 100
Sort By:
European Urology Oncology|November 5, 2025
Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS TrialJoan Carles, Bertrand Tombal, Maha Hussain, et al.
Prostate Cancer and Prostatic Diseases|February 22, 2022
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)Daniel J George, Neeraj Agarwal, Oliver Sartor, et al.
Urologic Oncology|July 28, 2022
Impact of the primary tumor location on secondary sites and overall mortality in patients with metastatic upper tract urothelial carcinomaClaudia Collà Ruvolo, Marina Deuker, Mike Wenzel, et al.
Future Oncology (London, England)|January 17, 2022
A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancerNeeraj Agarwal, Arun Azad, Joan Carles, et al.
The Prostate|September 13, 2021
Increased risk of postoperative in-hospital complications after radical prostatectomy in patients with prior organ transplantMike Wenzel, Christoph Würnschimmel, Francesco Chierigo, et al.
The Canadian Journal of Urology|July 14, 2005
Canadian guidelines for the management of benign prostatic hyperplasiaJ Curtis Nickel, Sender Herschorn, Jacques Corcos, et al.
International Journal of Clinical Oncology|June 6, 2021
Comparison between 1973 and 2004/2016 World Health Organization grading in upper tract urothelial carcinoma treated with radical nephroureterectomyClaudia Collà Ruvolo, Christoph Würnschimmel, Mike Wenzel, et al.
BJU International|August 17, 2018
Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancerMichel Wissing, Fadi Brimo, Simone Chevalier, et al.
The Prostate|April 1, 2018
The impact of intraductal carcinoma of the prostate on the site and timing of recurrence and cancer-specific survivalVincent Q Trinh, Jennifer Sirois, Nazim Benzerdjeb, et al.
The Journal of Pathology|April 30, 2009
PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancerKanishka Sircar, Maisa Yoshimoto, Federico A Monzon, et al.
Pageof 100

Showing results (511-520 of 993) with videos related to

Sort By:
Pageof 100
European Urology Oncology|November 5, 2025
Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS TrialJoan Carles, Bertrand Tombal, Maha Hussain, et al.
Prostate Cancer and Prostatic Diseases|February 22, 2022
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)Daniel J George, Neeraj Agarwal, Oliver Sartor, et al.
Urologic Oncology|July 28, 2022
Impact of the primary tumor location on secondary sites and overall mortality in patients with metastatic upper tract urothelial carcinomaClaudia Collà Ruvolo, Marina Deuker, Mike Wenzel, et al.
Future Oncology (London, England)|January 17, 2022
A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancerNeeraj Agarwal, Arun Azad, Joan Carles, et al.
The Prostate|September 13, 2021
Increased risk of postoperative in-hospital complications after radical prostatectomy in patients with prior organ transplantMike Wenzel, Christoph Würnschimmel, Francesco Chierigo, et al.
The Canadian Journal of Urology|July 14, 2005
Canadian guidelines for the management of benign prostatic hyperplasiaJ Curtis Nickel, Sender Herschorn, Jacques Corcos, et al.
International Journal of Clinical Oncology|June 6, 2021
Comparison between 1973 and 2004/2016 World Health Organization grading in upper tract urothelial carcinoma treated with radical nephroureterectomyClaudia Collà Ruvolo, Christoph Würnschimmel, Mike Wenzel, et al.
BJU International|August 17, 2018
Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancerMichel Wissing, Fadi Brimo, Simone Chevalier, et al.
The Prostate|April 1, 2018
The impact of intraductal carcinoma of the prostate on the site and timing of recurrence and cancer-specific survivalVincent Q Trinh, Jennifer Sirois, Nazim Benzerdjeb, et al.
The Journal of Pathology|April 30, 2009
PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancerKanishka Sircar, Maisa Yoshimoto, Federico A Monzon, et al.
Pageof 100